Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on Vericel. The associated price target remains the same with $55.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Josh Jennings has given his Buy rating due to a combination of factors that suggest Vericel is poised for significant growth. The company is expected to benefit from historical seasonality patterns, particularly in the fourth quarter, which traditionally accounts for a substantial portion of annual MACI sales. Additionally, Vericel’s strategic initiatives, such as expanding its salesforce by 30% and increasing the number of Arthro-trained surgeons, are designed to capitalize on peak demand periods and drive revenue growth.
Furthermore, Vericel’s record biopsy volumes in the first half of 2025 and the acceleration of MACI volume growth in July indicate a robust pipeline and growing market adoption. The company’s efforts to penetrate new defect segments and favorable reimbursement and pricing dynamics further bolster the outlook. These elements, combined with early positive indicators, support the expectation of achieving low-20% MACI revenue growth in 2025 and sustaining momentum into 2026, reinforcing Jennings’s confidence in the Buy rating.
In another report released on September 24, Canaccord Genuity also reiterated a Buy rating on the stock with a $58.00 price target.